The total market size of eosinophilic esophagitis in 2023 was approximately USD 1.80 trillion in the 7MM, which is expected to grow during the forecast period (2020-2034). Among EU4 and the UK, ...

“Both companies are ‘houses of brands’, in other words a collection of well-diversified luxury businesses serving multiple ...

Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent ... for severe eosinophilic asthma, making $1.3 billion in sales last year. It is also being developed for other indications including ...

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU ... Potential in asthma The drug is also set to gain further indications in further inflammation-related diseases, most notably ...

[32] Therefore, chronic urticaria and/or angioedema are not considered indications ... of asthma[100,101] 1965: Lowell and Franklin demonstrated the specificity of immunotherapy in ragweed ...

"This study really looked at preventing accidental ingestions, preventing anaphylaxis, and just making life a little easier ...

Inflammation is a crucial part of the body's defense mechanism, playing a key role in fighting infections and repairing ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

These cells gather in the lungs and appear to cause the most harm in men who develop asthma in later ... Toddlers Allergic to Peanuts: Study Shows How Sublingual Immunotherapy Is Safe and ...

Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by ...